Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on October 28, 2007, reporting a material definitive agreement. Specifically, on October 24, 2007, the company entered into a First Amendment to Lease for its new corporate headquarters and research and development complex. This amendment significantly increases the leased space, expanding the facility from approximately 221,000 to 257,000 square feet.
Key Highlights
- 1Regeneron Pharmaceuticals has amended its lease agreement for a new corporate headquarters and R&D complex.
- 2The amendment increases the total leased space from approximately 221,000 to 257,000 square feet.
- 3The expanded facility will include approximately 27,000 square feet of currently occupied space and 230,000 square feet in new construction.
- 4The new complex is adjacent to the company's current facility in Tarrytown, New York.
- 5The original lease agreement was entered into on December 21, 2006.
- 6The filing indicates that the full amendment will be filed with the company's Form 10-Q for the period ending September 30, 2007.